Epidermal growth factor-induced truncation of the epidermal growth factor receptor
نویسندگان
چکیده
منابع مشابه
Altered Expression of Epidermal Growth Factor Receptor (EGFR) in Glioma
EGFR is a key molecule in cancer cells. EGFR signaling was shown to promote tumor cell proliferation and survival, invasion and angiogenesis and mediate resistance to treatment, including ionizing radiation in preclinical models. We extracted proteins from astrocytoma (III and IV) oligodendroglioma(IV) tumors and normal brain tissues and then evaluated the protein purity by Bradford test ...
متن کاملAssessment of epidermal growth factor receptor status in glioblastomas
Objective(s): Our previous study showed that a newly designed tracer radioiodinated 6-(3-morpholinopropoxy)-7-ethoxy-4-(3'-iodophenoxy)quinazoline ([125I]PYK) is promising for the evaluation of the epidermal growth factor receptor (EGFR) status and prediction of gefitinib treatment of non-small cell lung cancer. EGFR is over-expressed and mutated also in glioblastoma. In the present study, the ...
متن کاملEpidermal Growth Factor Receptor
A monoclonal antibody to the epidermal growth factor (EGF) receptor of A431 cells, denoted 2Dl-IgM, was generated after fusion of immunized BALB/c mouse spleen cells with SpZ/O-Ag14 myeloma cells, Specific binding of 2D1-IgM to the A431 cell-surface receptor for EGF was demonstrated by indirect immunofluorescence, immunoprecipitation, and immunoblot analysis. Scatchard analysis of lz6I-EGF bi...
متن کاملEpidermal growth factor receptor signaling
The epidermal growth factor receptor (EGFR) is a long known, versatile signal transducer that has been well conserved during evolution. It functions in a wide range of cellular processes including cell fate determination, proliferation, cell migration and apoptosis. The activity of the EGFR is subject to modulation by multiple positive and negative regulators and is transduced to the nucleus by...
متن کاملEpidermal Growth Factor Receptor Pathway
Erlotinib is an orally small molecule inhibiting the tyrosine kinase activity of the epidermal growth factor receptor (EGFR). Currently, erlotinib, at a standard oral daily dose of 150 mg, is licensed for the treatment of unselected recurrent non-small cell lung cancer (NSCLC) patients, however, it is being investigated in all stages of NSCLC. Erlotinib is well tolerated, with common toxicities...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Biological Chemistry
سال: 1989
ISSN: 0021-9258
DOI: 10.1016/s0021-9258(19)84617-3